Hudson Canyon Capital Management Abb Vie Inc. Transaction History

Hudson Canyon Capital Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 02, 2023	SELL	$132.51 - $164.9 $1.47 Million - $1.83 Million	-11,089 Closed	0 $0
Q1 2023 Aug 02, 2023	SELL	$144.61 - $166.54 $96,599 - $111,248	-668 Reduced 5.68%	11,089 $1.77 Billion
Q4 2022 Aug 02, 2023	SELL	$138.31 - $165.87 $35,683 - $42,794	-258 Reduced 2.15%	11,757 $1.9 Billion
Q2 2022 Aug 02, 2023	BUY	$137.62 - $174.96 $236,018 - $300,056	1,715 Added 16.65%	12,015 $1.84 Billion
Q1 2022 Aug 02, 2023	BUY	$131.98 - $163.75 $1.36 Million - $1.69 Million	10,300 New	10,300 $1.67 Billion

3,693

1.27B

13M

9.79M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $342B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Hudson Canyon Capital Management, based on Form 13F filings with the SEC.

Stay updated on Hudson Canyon Capital Management with notifications on news.